The drugs are effective, however, at reducing cardiovascular risks in CKD patients

AMLODIPINE TREATMENT may reduce cardiovascular risks in hypertensive hemodialysis patients, according to German researchers.

An FDA analysis provides new evidence that the use of statins does not increase incidence of amyotrophic lateral sclerosis (ALS), the neurodegenerative disorder commonly called "Lou Gehrig's disease."

Oxford BioMedica, a leading gene therapy company in the United Kingdom, has announced an agreement with the FDA concerning a series of amendments to its phase 3 study of TroVax, a novel therapeutic vaccine for renal cancer.

Understanding how various sperm proteins function could lead to new methods of diagnosing and treating infertility, according to researchers.

Interrad Medical, Inc., of Plymouth, Minn., has received clearance of its SecurAcath peripherally inserted central catheter (PICC) with Subcutaneous Securement System, which deploys a small anchor in the subcutaneous tissue just beneath the skin to hold an indwelling catheter securely in place.

Rapaflo (silodosin), an alpha blocker marketed by Watson Pharmaceuticals, Inc., in Corona, Calif., for oral, once-daily treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) has received approval.

Smoking, obesity, and physical activity are risk factors for renal cell carcinoma (RCC) incidence and mortality, a study found.

Robotic radical prostatectomies can be performed with a new technique that obviates the need for urethral catheters, sparing patients penile shaft and tip pain, according to investigators.

Nephrologists from around the world have banded together to issue a strongly worded series of statements intended to stem organ trafficking and transplant tourism.